DiscoveryProbe™ FDA-approved Drug Library: Enabling Mechanism-Based Drug Repositioning for Rare and Complex Diseases

Introduction

The landscape of drug discovery is evolving rapidly, driven by the need for efficient identification of novel therapeutics and a deeper mechanistic understanding of disease biology. The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) stands at the forefront of this transformation, offering a meticulously curated, FDA-approved bioactive compound library for high-throughput and high-content screening. While previous literature has spotlighted its impact on oncology, neurodegeneration, and osteoarthritis, this article delves into a less-explored yet crucial application: utilizing mechanism-based screening to unlock drug repositioning opportunities in rare and complex diseases, such as mucopolysaccharidosis-plus syndrome (MPSPS), through signal pathway regulation and enzyme inhibitor screening.

Mechanism of Action and Distinctive Features of the DiscoveryProbe™ Library

Comprehensive Bioactive Compound Coverage

The DiscoveryProbe™ FDA-approved Drug Library encompasses 2,320 clinically approved compounds, each with well-characterized mechanisms—ranging from receptor agonists/antagonists and enzyme inhibitors to ion channel modulators and signaling pathway regulators. Each compound, including clinical mainstays such as doxorubicin, metformin, and atorvastatin, is validated for bioactivity and regulatory approval by agencies such as the FDA, EMA, HMA, CFDA, and PMDA, or is listed in recognized pharmacopeias. This breadth ensures that the library is not simply a collection of drugs, but a functional repertoire for dissecting complex biological mechanisms and identifying pharmacological targets.

Ready-to-Use, High-Throughput Formats

The compounds are supplied as pre-dissolved 10 mM DMSO solutions, available in industry-standard 96-well microplates, deep-well plates, and 2D barcoded storage tubes—enabling seamless integration into automated screening workflows. Stability is ensured for 12 months at -20°C and up to 24 months at -80°C, with flexible shipping options tailored to laboratory needs. This design supports both high-throughput screening drug library experiments and high-content screening compound collection applications, bolstering reproducibility and efficiency in translational research.

Integrating Mechanism-Based Screening: From Rare Diseases to Complex Pathways

Beyond Common Indications: Addressing Rare and Underserved Diseases

Traditional drug screening often focuses on prevalent diseases, yet the greatest unmet needs persist in rare and mechanistically complex disorders. The DiscoveryProbe™ library enables researchers to conduct unbiased, mechanism-driven screens across a wide spectrum of disease models. A striking illustration comes from the recent study by Terawaki et al. (iScience, 2025), where an FDA-approved drug library was leveraged to identify triclabendazole as a promising candidate for mucopolysaccharidosis-plus syndrome (MPSPS)—a devastating lysosomal storage disorder with no current cure.

In this context, the high-content screening compound collection facilitated the discovery of triclabendazole's ability to reduce glycosaminoglycan (GAG) accumulation, offering new hope for patients with MPSPS and related pathologies. Notably, the screening not only identified a new therapeutic avenue but also illuminated the underlying molecular mechanisms, such as the regulation of autophagy and endocytic trafficking via the VPS33A gene. This demonstrates the power of the DiscoveryProbe™ library for drug repositioning screening in rare disease landscapes that lack robust animal models or established enzymatic targets.

Signal Pathway Regulation and Enzyme Inhibitor Screening

With its diverse array of compounds, the DiscoveryProbe™ FDA-approved Drug Library is uniquely positioned to interrogate cellular signaling networks and enzymatic pathways. Whether investigating kinase cascades involved in cancer progression or the role of small molecule regulators in neurodegenerative disease drug discovery, the library provides a platform for targeted and phenotypic assays alike. The inclusion of both orthosteric and allosteric modulators enables nuanced interrogation of pathway nodes, supporting the identification of novel pharmacological targets and the repurposing of existing drugs for new indications.

Comparative Analysis: Distinctive Value Versus Alternative Approaches

Existing cornerstone articles have highlighted the DiscoveryProbe™ library’s strategic value in translational drug discovery, particularly in oncology and ECM-related diseases. For instance, the article "Unlocking Translational Breakthroughs: Mechanistic Insight with the DiscoveryProbe™ FDA-approved Drug Library" provides actionable guidance for accelerating therapeutic innovation, focusing on ChaC1-based screening and competitive pipeline mapping. While this perspective emphasizes broad translational workflows and mechanistic insight in established disease categories, the current article distinguishes itself by concentrating on rare disease applications and the molecular dissection of signaling pathways—an area less elaborated in previous works.

Similarly, the article "DiscoveryProbe™ FDA-approved Drug Library: Transforming Osteoarthritis Research" explores ECM modulation and osteoarthritis, whereas our discussion extends the utility of the high-throughput screening drug library to emerging rare disease models, integrating recent scientific advances and offering a blueprint for mechanism-based drug repositioning beyond traditional indications. This approach ensures that the versatile capabilities of the DiscoveryProbe™ library are fully harnessed, even in areas where preclinical models are scarce or disease mechanisms are not fully elucidated.

Advanced Applications in Life Sciences Research

Accelerating Drug Repositioning Screening

Drug repositioning—repurposing existing drugs for novel indications—has emerged as a powerful strategy to shorten development timelines and reduce risk. The DiscoveryProbe™ FDA-approved Drug Library is optimized for this paradigm, enabling rapid screening for new therapeutic effects across a spectrum of validated pharmacological agents. The aforementioned study by Terawaki et al. (2025) exemplifies this process, demonstrating how a mechanism-driven screen can uncover unexpected therapeutic actions—such as triclabendazole’s suppression of GAG accumulation—by leveraging known drugs in new disease contexts.

Cancer and Neurodegenerative Disease Research

Building upon the established role of the DiscoveryProbe™ library in cancer research drug screening and neurodegenerative disease drug discovery, researchers can utilize its broad mechanistic repertoire to identify compounds that modulate key oncogenic pathways, apoptosis, or neuroprotective processes. While prior work like "From Mechanism to Medicine: Transforming Translational Research" has detailed its contributions in bridging discovery and clinical impact for these indications, our focus on rare and mechanistically complex diseases highlights additional frontiers where mechanism-based screening can reveal new therapeutic strategies.

Pharmacological Target Identification and Signaling Pathway Dissection

High-throughput and high-content screening platforms powered by the DiscoveryProbe™ FDA-approved Drug Library enable researchers to systematically interrogate diverse biological processes—ranging from autophagy, endocytosis, and signal transduction to metabolic regulation. This facilitates the identification of novel pharmacological targets, especially in diseases where conventional target-based approaches have stalled. By integrating compounds with known mechanisms, the library allows for the deconvolution of complex phenotypic outcomes, accelerating the path from target identification to lead optimization.

Technical Implementation and Workflow Integration

The library’s pre-dissolved, barcoded format streamlines integration with automated liquid handling and data management systems, enabling scalable, reproducible, and high-throughput experimentation. This infrastructure supports not only primary screening but also follow-up validation and mechanistic studies, ensuring that hits can be rapidly prioritized and advanced through the drug discovery pipeline. The flexibility in plate and tube formats further accommodates both screening core facilities and individual investigator-driven projects.

Case Study: Triclabendazole and Mucopolysaccharidosis-Plus Syndrome

The recent identification of triclabendazole as a candidate therapeutic for MPSPS (Terawaki et al., 2025) underscores the transformative potential of the DiscoveryProbe™ FDA-approved Drug Library for rare disease research. By systematically screening a diverse set of FDA-approved compounds, the authors were able to pinpoint a drug that not only reduced GAG accumulation in patient-derived cells and animal models, but also provided mechanistic insight into the role of VPS33A in autophagy and endocytic trafficking. This approach could be readily extended to other lysosomal storage disorders, metabolic diseases, or even complex neurodegenerative syndromes, leveraging the library's mechanistic diversity and regulatory validation to expedite translational breakthroughs.

Conclusion and Future Outlook

The DiscoveryProbe™ FDA-approved Drug Library represents a paradigm shift in how researchers approach high-throughput screening, drug repositioning, and pharmacological target identification—especially in rare and mechanistically complex diseases. By enabling systematic, mechanism-based interrogation of bioactive compounds, the library accelerates the discovery of novel therapeutics and provides deep insight into disease biology.

While prior articles have mapped its impact in established fields such as oncology and neurodegeneration (see, for example, "Benchmarks, Mechanistic Insight, and Translational Impact" for a comparative performance analysis), this article uniquely emphasizes its utility in rare disease models, mechanistic pathway dissection, and enzyme inhibitor screening. As advances in genomics and systems biology continue to reveal new layers of disease complexity, the need for versatile, mechanism-driven screening platforms like the DiscoveryProbe™ FDA-approved Drug Library will only intensify. Researchers seeking to bridge the gap between molecular insight and clinical application—across both common and rare diseases—will find this resource indispensable for the next generation of life sciences innovation.